secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-06-15T12:15:16+00:00
Accession:  0001193125-26-270328
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora discontinues navacaprant after Phase 3 MDD failures; cuts workforce 35%
-------------------------------------------------------------------------------

- Navacaprant failed primary endpoint in KOASTAL-2 (p=0.813) and KOASTAL-3 (p=0.480); development discontinued.
- Company reducing workforce ~35%, expects ~$10M annualized savings, ~$2M restructuring costs in Q2 2026.
- Cash and cash equivalents expected to fund operations into Q3 2027.
- Pipeline focus shifts to NMRA-511 (Alzheimer's agitation), NMRA-898 (schizophrenia), NMRA-215 (obesity) with multiple milestones in H2 2026.
- Third Amendment to loan agreement extends interest-only period; minimum liquidity covenant tied to milestones or market cap effective July 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-270328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer